285 related articles for article (PubMed ID: 32326836)
21. Effects of Coexistent BRAF
Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
[TBL] [Abstract][Full Text] [Related]
22. Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population.
Argyropoulou M; Veskoukis AS; Karanatsiou PM; Manolakelli A; Kostoglou-Athanassiou I; Vilaras G; Karameris A; Liadaki K
Pathol Oncol Res; 2020 Jan; 26(1):347-354. PubMed ID: 30361901
[TBL] [Abstract][Full Text] [Related]
23. Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.
Hurst Z; Liyanarachchi S; He H; Brock P; Sipos J; Nabhan F; Kebebew E; Green P; Cote GJ; Sherman S; Walker CJ; Chang YS; Xue S; Hollingsworth B; Li W; Genutis L; Menq E; de la Chapelle A; Jhiang SM
Thyroid; 2019 Apr; 29(4):530-539. PubMed ID: 30654714
[TBL] [Abstract][Full Text] [Related]
24. Clinical Utility of BRAF, NRAS, and TERT Promoter Mutation in Preoperative Thyroid Fine-Needle Aspiration Biopsy: A Diagnostic Study From Dharmais Cancer Hospital.
Perdana AB; Putri RI; Rachmawati R; Andinata B; Brahma B
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3267-3277. PubMed ID: 33247684
[TBL] [Abstract][Full Text] [Related]
25. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors of outcome in poorly differentiated thyroid carcinomas.
de la Fouchardière C; Decaussin-Petrucci M; Berthiller J; Descotes F; Lopez J; Lifante JC; Peix JL; Giraudet AL; Delahaye A; Masson S; Bournaud-Salinas C; Borson Chazot F
Eur J Cancer; 2018 Mar; 92():40-47. PubMed ID: 29413688
[TBL] [Abstract][Full Text] [Related]
27.
Camargo Barros-Filho M; Barreto Menezes de Lima L; Bisarro Dos Reis M; Bette Homem de Mello J; Moraes Beltrami C; Lopes Pinto CA; Kowalski LP; Rogatto SR
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884810
[TBL] [Abstract][Full Text] [Related]
28. Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.
Soe MH; Chiang JM; Flavell RR; Khanafshar E; Mendoza L; Kang H; Liu C
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3206-e3216. PubMed ID: 35556126
[TBL] [Abstract][Full Text] [Related]
29. The role of the size in thyroid cancer risk stratification.
Vianello F; Censi S; Watutantrige-Fernando S; Barollo S; Zhu YH; Albiger N; Bertazza L; Manso J; Carducci S; Benna C; Iacobone M; Galuppini F; Pennelli G; Mian C
Sci Rep; 2021 Mar; 11(1):7303. PubMed ID: 33790328
[TBL] [Abstract][Full Text] [Related]
30. Genetic Alterations in Differentiated Thyroid Cancer Patients with Acromegaly.
Aydin K; Aydin C; Dagdelen S; Tezel GG; Erbas T
Exp Clin Endocrinol Diabetes; 2016 Mar; 124(3):198-202. PubMed ID: 26575115
[TBL] [Abstract][Full Text] [Related]
31. Radioactive iodine refractoriness in Middle Eastern differentiated thyroid cancer: clinical outcome and risk factor analysis.
Parvathareddy SK; Siraj AK; Siraj N; Ahmed SO; Al-Rasheed M; Qadri Z; Siddiqui K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Front Endocrinol (Lausanne); 2024; 15():1326976. PubMed ID: 38812819
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer.
Schumm MA; Shu ML; Hughes EG; Nikiforov YE; Nikiforova MN; Wald AI; Lechner MG; Tseng CH; Sajed DP; Wu JX; Yeh MW; Livhits MJ
JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):735-742. PubMed ID: 37382944
[TBL] [Abstract][Full Text] [Related]
33. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma.
Danilovic DL; Lima EU; Domingues RB; Brandão LG; Hoff AO; Marui S
Eur J Endocrinol; 2014 Apr; 170(4):619-25. PubMed ID: 24468978
[TBL] [Abstract][Full Text] [Related]
34. Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.
Yang J; Gong Y; Yan S; Chen H; Qin S; Gong R
Endocrine; 2020 Jan; 67(1):44-57. PubMed ID: 31655978
[TBL] [Abstract][Full Text] [Related]
35. Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer.
Mu Z; Zhang X; Liang D; Fang J; Chen G; Guo W; Sun D; Sun Y; Kai Z; Huang L; Liang J; Lin Y
Chin J Cancer Res; 2024 Feb; 36(1):25-35. PubMed ID: 38455372
[TBL] [Abstract][Full Text] [Related]
36. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer.
Song YS; Lim JA; Min HS; Kim MJ; Choi HS; Cho SW; Moon JH; Yi KH; Park DJ; Cho BY; Park YJ
Eur J Endocrinol; 2017 Dec; 177(6):465-473. PubMed ID: 28864536
[TBL] [Abstract][Full Text] [Related]
37. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
[TBL] [Abstract][Full Text] [Related]
38.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
39. Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.
Xu B; Tuttle RM; Sabra MM; Ganly I; Ghossein R
Thyroid; 2017 May; 27(5):632-640. PubMed ID: 28049366
[TBL] [Abstract][Full Text] [Related]
40. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
